Rx Only

cobas® Malaria

For in vitro diagnostic use

IVD

cobas® Malaria – 192	P/N: 09352511190
cobas® Malaria Control Kit	P/N: 09352520190
cobas® NHP Negative Control Kit	P/N: 09051554190
cobas® omni MGP Reagent	P/N: 06997546190
cobas® omni Specimen Diluent	P/N: 06997511190
cobas® omni Lysis Reagent	P/N: 06997538190
cobas® omni Wash Reagent	P/N: 06997503190

Table of contents

Intended use

The **cobas**® Malaria test for use on the **cobas**® 5800/6800/8800 Systems (**cobas**® Malaria) is a qualitative in vitro nucleic acid screening test for the direct detection of *Plasmodium* (*P. falciparum, P. malariae, P. vivax, P. ovale* and *P. knowlesi*) DNA and RNA in whole blood samples from individual human donors, including donors of whole blood and blood components, as well as other living donors. It is also intended for use in testing whole blood samples to screen organ and tissue donors when samples are obtained while the donor's heart is still beating.

Whole blood samples from all donors may be screened as individual samples. For donations of whole blood and blood components, whole blood samples may be tested individually or in pools comprised of aliquots of individual samples.

The test is not intended for use as an aid in diagnosis of *Plasmodium* infection.

This test is not intended for use on samples of cord blood.

This test is not intended for use on cadaveric samples.

Summary and explanation of the test

Background

Malaria is caused by the infection of red blood cells with intracellular protozoan parasites of the genus *Plasmodium*. Malaria initially presents as a febrile illness and, if left untreated, can rapidly progress to a life-threatening disease with symptoms including severe anemia, respiratory distress (due to metabolic acidosis), cerebral malaria and multi-organ failure.[1,2]

Five *Plasmodium* species cause malaria in humans (*P. falciparum, P. malariae, P. vivax, P. ovale,* and *P. knowlesi*). Of these, 2 species—*P. falciparum* and *P. vivax*—are the major contributors to human morbidity.[2,3]

Parasites are usually transmitted to people through the bite of an infected female *Anopheles* mosquito. Malaria can also be transmitted via transfusion (transfusion-transmitted malaria [TTM]), when blood or a blood component from a malaria-infected donor is transfused to a patient, or from mother to child during pregnancy or delivery.[3,4] TTM may cause severe clinical symptoms in the recipients, especially in those with no previous exposure to malaria or in individuals who are immunocompromised due to other coexisting diseases.[5]

TTM can occur in both endemic and non-endemic areas. In non-endemic areas, TTM is usually the result of blood or a blood product collected from a donor who was infected during travel to malaria-endemic areas or from chronically infected immigrants from endemic areas.[5,6] In the United States (US), blood collection centers use a donor questionnaire that includes questions about travel to or living in malaria-endemic areas so that donors who may be at risk for malaria may be deferred from donating. Use of a questionnaire to exclude donors based on risk (such as from travel to or a history of residence in a malaria-endemic country) likely results in deferral of many prospective donors who are not infected with malaria. The use of a highly sensitive nucleic acid test (NAT) to screen donors for actual presence of *Plasmodium* could result in deferral of significantly fewer donors.

Rationale for NAT testing

Malaria can be transmitted via transfusion.[3] The US Food and Drug Administration does not currently require testing of blood donors for malaria. Serologic tests are not sufficiently sensitive or inclusive to be used in the setting of donor screening. Instead, donors with a recent travel history or residence in malaria-endemic countries are deferred from donation. These deferrals reduce the number of available donors and may reduce the amount of blood and blood products available for transfusion. A NAT test with high sensitivity for the 5 *Plasmodium* species that cause human disease could be used to screen donor samples, offering an alternative strategy to deferral to keep malaria out of the blood supply. Blood donations infected with *Plasmodium* could be identified, interdicted, and discarded. **cobas**® Malaria will offer the novel capability to detect *Plasmodium* in blood donations, thereby providing heightened protection from TTM infection for recipients of donated blood components or products and further improving the safety of the blood supply. In endemic areas, the current practice is to use antigen testing or microscopy to screen donations,[4] but these lack sufficient sensitivity to detect all potentially infectious units.[7] In non-endemic countries, questionnaires exclude many donors who are not infected and fail to exclude some who are infected.[7] In some non-endemic countries, serology tests are used to qualify donors who indicate a malaria risk on their donor screening questionnaires, but the available serology assays show variable detection and poor agreement.[8,9]

Explanation of the test

cobas® Malaria is a qualitative PCR test for the detection of *Plasmodium* (*P. falciparum, P. malariae, P. vivax, P. ovale* and *P. knowlesi*) DNA and RNA that is run on the **cobas**® 5800/6800/8800 Systems. **cobas**® Malaria detects five species of Malaria: *Plasmodium falciparum* (most prevalent), *P. malariae*, *P. vivax*, *P. ovale*, and *P. knowlesi*. Of these, 2 species—*P. falciparum* and *P. vivax*—are the major contributors to human morbidity.

Principles of the procedure

cobas® Malaria is based on a fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection.

The **cobas**® 5800 System consists of a single, integrated instrument. The **cobas**® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the **cobas**® 5800 or the **cobas**® 6800/8800 Systems software, which assigns test results for all tests as either non-reactive, reactive or invalid. When using the **cobas**® 6800/8800 Systems, results can be reviewed directly on the system screen, printed as a report, or sent to a Laboratory Information Management System (LIMS) or other result management system.

Samples should be tested as individual samples or, optionally, can be tested in pools consisting of aliquots of individual samples.

If pooling in a pre-analytical step is performed, the **cobas**® **Synergy** software with the Hamilton MICROLAB® STAR/STARlet IVD may be used.

Whole blood may be collected in the designated Roche Whole Blood Collection Tube. Alternatively whole blood may be collected in EDTA anticoagulant and transferred manually to the Roche Whole Blood Collection Tube. The Roche Whole Blood Collection Tube contains a pre-analytic, guanidine-based, chaotropic reagent, used to lyse cells within the whole blood, releasing and preserving nucleic acids. The tube containing the lysed whole blood is the primary tube on the analyzer, on which the universal sample preparation steps will be performed by the **cobas**® 5800/6800/8800 Systems.

Armored RNA internal control (IC) molecules are added during universal sample preparation and serves as a full process control from sample preparation through amplification/detection. The IC monitors for interference that could cause false negative results. Potentially affected samples are invalidated.

The test also utilizes two external controls: a positive and a negative control. In addition to the sample lysis and release of nucleic acid which occurs in the primary tube, nucleic acids are also released by addition of proteinase and lysis reagent to the sample and controls. The released nucleic acids bind to the silica surface of the magnetic glass particles, which are added to the sample. Unbound substances and impurities, such as denatured proteins, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acids are eluted from the glass particles with elution buffer at elevated temperature.

Selective amplification of target nucleic acid from the donor sample is achieved by the use of specific forward and reverse primers which are selected from highly conserved regions of the target nucleic acid. A thermostable DNA polymerase enzyme is used for both reverse-transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon).[10-12] Any contaminating amplicons from previous PCR runs are destroyed by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR mix, when heated in the first thermal cycling step. Newly formed amplicons are not destroyed since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.

The **cobas**® Malaria master mix contains detection probes which are specific for *Plasmodium* and IC nucleic acid. The specific *Plasmodium* and IC detection probes are each labeled with one of two unique fluorescent dyes which act as a reporter. Each probe also has a second dye which acts as a quencher. The reporter dyes is measured at a defined wavelength, thus permitting detection and discrimination of the amplified *Plasmodium* targets and the IC.[13,14] When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dyes are concomitantly increased. Since the two specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified *Plasmodium* targets and the IC are possible.

Reagents and materials

cobas® Malaria reagents and controls

All unopened reagents and controls shall be stored as recommended in Table 1 to Table 4.

Table 1 cobas® Malaria test

cobas® Malaria test

Store at 2-8°C

192 test cassette (P/N 09352511190)

Kit components	Reagent ingredients	Quantity per kit 192 tests
Proteinase Solution (PASE)	Tris buffer, < 0.05% EDTA, calcium chloride, calcium acetate, 8% (w/v) proteinase, glycerol EUH210: Safety data sheets available on request. EUH208: Contains Subtilisin from Bacillus subtilis. May produce an allergic reaction.	22.3 mL
Internal Control (IC)	Tris buffer, < 0.05% EDTA, < 0.001% internal control armored RNA construct (non-infectious RNA encapsulated in MS2 bacteriophage), < 0.002% Poly rA RNA (synthetic), < 0.1% sodium azide	21.2 mL
Elution Buffer (EB)	Tris buffer, 0.2% methyl-4 hydroxybenzoate	21.2 mL
Master Mix Reagent 1 (MMX-R1)	Manganese acetate, potassium hydroxide, < 0.1% sodium azide	7.5 mL
Malaria Master Mix Reagent 2 (Malaria MMX-R2)	Tricine buffer, potassium acetate, glycerol, 18% dimethyl sulfoxide, Tween 20, EDTA, < 0.06% dATP, dGTP, dCTP, < 0.14% dUTP, < 0.01% upstream and downstream *Plasmodium* and internal control primers, < 0.01% fluorescent-labeled *Plasmodium* probes, < 0.01% fluorescent-labeled internal control probe, < 0.01% oligonucleotide aptamer, < 0.01% Z05D DNA polymerase, < 0.01% AmpErase (uracil-N-glycosylase) enzyme (microbial), < 0.1% sodium azide	9.7 mL

Table 2 **cobas**® Malaria Control Kit

cobas® Malaria Control Kit

Store at 2-8°C

(P/N 09352520190)

Kit components	Reagent ingredients	Quantity per kit	Safety symbol and warning*
Malaria Positive Control (Malaria (+) C)	< 0.001% Synthetic (armored) *Plasmodium* RNA encapsulated in MS2 bacteriophage coat protein, normal human plasma, *Plasmodium* DNA and RNA not detectable by PCR methods. < 0.1% ProClin® 300 preservative**	10.4 mL (16 x 0.65 mL)	 **WARNING** H317: May cause an allergic skin reaction. H412: Harmful to aquatic life with long lasting effects. P261: Avoid breathing mist or vapours. P273: Avoid release to the environment. P280: Wear protective gloves. P333 + P313: If skin irritation or rash occurs: Get medical advice/ attention. P362 + P364: Take off contaminated clothing before reuse. P501: Dispose of contents/ container to an approved waste disposal plant. 55965-84-9 reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1)

* Product safety labeling primarily follows EU GHS guidance

**Hazardous substance

Table 3 cobas® NHP Negative Control Kit

cobas® NHP Negative Control Kit

Store at 2-8°C

(P/N 09051554190)

Kit components	Reagent ingredients	Quantity per kit	Safety symbol and warning*
Normal Human Plasma Negative Control (NHP-NC)	Normal human plasma, *Plasmodium* DNA and RNA not detectable by PCR methods. < 0.1% ProClin® 300 preservative**	16 mL (16 x 1 mL)	 **WARNING** H317: May cause an allergic skin reaction. P261: Avoid breathing mist or vapours. P272: Contaminated work clothing should not be allowed out of the workplace. P280: Wear protective gloves. P333 + P313: If skin irritation or rash occurs: Get medical advice/ attention. P362 + P364: Take off contaminated clothing before reuse. P501: Dispose of contents/ container to an approved waste disposal plant. 55965-84-9 reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1)

* Product safety labeling primarily follows EU GHS guidance

**Hazardous substance

cobas® omni reagents for sample preparation

Table 4 cobas® omni reagents for sample preparation

Reagents	Reagent ingredients	Quantity per kit	Safety symbol and warning**
cobas® omni MGP Reagent (MGP) Store at 2–8°C (P/N 06997546190)	Magnetic glass particles, Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide	480 tests	Not applicable
cobas® omni Specimen Diluent (SPEC DIL) Store at 2–8°C (P/N 06997511190)	Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide	4 x 875 mL	Not applicable
cobas® omni Lysis Reagent (LYS) Store at 2–8°C (P/N 06997538190)	42.56% (w/w) guanidine thiocyanate***, 5% (w/v) polydocanol***, 2% (w/v) dithiothreitol***, dihydro sodium citrate	4 x 875 mL	 **DANGER** H302: Harmful if swallowed. H314: Causes severe skin burns and eye damage. H412: Harmful to aquatic life with long lasting effects. EUH032: Contact with acids liberates very toxic gas. EUH071: Corrosive to the respiratory tract. P273: Avoid release to the environment. P280: Wear protective gloves/ protective clothing/eye protection/ face protection/ hearing protection. P301 + P330 + P331: IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. P303 + P361 + P353: IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water. P304 + P340 + P310: IF INHALED: Remove person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER/ doctor. P305 + P351 + P338 + P310: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor. 593-84-0 Guanidinium thiocyanate 9002-92-0 Polidocanol 3483-12-3 (R*,R*)-1,4-dimercaptobutane-2,3-diol
cobas® omni Wash Reagent (WASH) Store at 15–30°C (P/N 06997503190)	Sodium citrate dihydrate, 0.1% methyl-4 hydroxybenzoate	4.2 L	Not applicable

* These reagents are not included in the **cobas**® Malaria test kit. See listing of additional materials required (Table 9).

** Product safety labeling primarily follows EU GHS guidance.

***Hazardous substance

Reagent storage and handling requirements

Reagents shall be stored and will be handled as specified in Table 5 and Table 7.

When reagents are not loaded on the **cobas**® 5800/6800/8800 Systems, store them at the corresponding temperature specified in Table 5.

Table 5 Reagent storage (when reagent is not on the system)

Reagent	Storage temperature
cobas® Malaria - 192	2–8°C
cobas® Malaria Control Kit	2–8°C
cobas® NHP Negative Control Kit	2–8°C
cobas® **omni** Lysis Reagent	2–8°C
cobas® **omni** MGP Reagent	2–8°C
cobas® **omni** Specimen Diluent	2–8°C
cobas® **omni** Wash Reagent	15–30°C

Reagent handling requirements for the cobas® 5800 System

Reagents loaded onto the **cobas**® 5800 System are stored at appropriate temperatures and their expiration is monitored by the system. The system allows reagents to be used only if all of the conditions shown in Table 6 are met. The system automatically prevents use of expired reagents. Table 6 allows the user to understand the reagent handling conditions enforced by the **cobas**® 5800 System.

Table 6 Reagent expiry conditions enforced by the **cobas**® 5800 System

Reagent	Kit expiration date	Open-kit stability	Number of runs for which this kit can be used	On-board stability
cobas® Malaria – 192	Date not passed	90 days from first usage*	Max 40 runs	Max. 36 days
cobas® Malaria Control Kit	Date not passed	Not applicable[a]	Not applicable	Max 36 days
cobas® NHP Negative Control Kit	Date not passed	Not applicable[a]	Not applicable	Max 36 days
cobas® **omni** Lysis Reagent	Date not passed	30 days from loading*	Not applicable	Not applicable
cobas® **omni** MGP Reagent	Date not passed	30 days from loading*	Not applicable	Not applicable
cobas® **omni** Specimen Diluent	Date not passed	30 days from loading*	Not applicable	Not applicable
cobas® **omni** Wash Reagent	Date not passed	30 days from loading*	Not applicable	Not applicable

[a] Single use reagents

* Time is measured from the first time that reagent is loaded onto the **cobas**® 5800 System.

Reagent handling requirements for the cobas® 6800/8800 Systems

Reagents loaded onto the **cobas**® 6800/8800 Systems are stored at appropriate temperatures and their expiration is monitored by the system. The systems allow reagents to be used only if all of the conditions shown in Table 7 are met. The systems automatically prevent use of expired reagents. Table 7 allows the user to understand the reagent handling conditions enforced by the **cobas**® 6800/8800 Systems.

Table 7 Reagent expiry conditions enforced by the **cobas**® 6800/8800 Systems

Reagent	Kit expiration date	Open-kit stability	Number of runs for which this kit can be used	On-board stability (cumulative time on board outside refrigerator)
cobas® Malaria – 192	Date not passed	90 days since loading*	Max 40 runs	Max 40 hours
cobas® Malaria Control Kit	Date not passed	Not applicable[a]	Not applicable	Max 10 hours
cobas® NHP Negative Control Kit	Date not passed	Not applicable[a]	Not applicable	Max 10 hours
cobas® **omni** Lysis Reagent	Date not passed	30 days since loading*	Not applicable	Not applicable
cobas® **omni** MGP Reagent	Date not passed	30 days since loading*	Not applicable	Not applicable
cobas® **omni** Specimen Diluent	Date not passed	30 days since loading*	Not applicable	Not applicable
cobas® **omni** Wash Reagent	Date not passed	30 days since loading*	Not applicable	Not applicable

[a] Single use reagents

* Time is measured from the first time that reagent is loaded onto the **cobas**® 6800/8800 Systems.

Additional materials required for the cobas® 5800 System

Table 8 Materials and consumables for use on **cobas**® 5800 System

Material	P/N
Roche Whole Blood Collection Tube	08827907001
cobas® **omni** Processing Plate 24	08413975001
cobas® **omni** Amplification Plate 24	08499853001
cobas® **omni** Liquid Waste Plate 24	08413983001
CORE Tips with Filter, 1 mL	04639642001
CORE Tips with Filter, 300 µL	07345607001
cobas® **omni** Liquid Waste Container	07094388001
cobas® **omni** Lysis Reagent	06997538190
cobas® **omni** MGP Reagent	06997546190
cobas® **omni** Specimen Diluent	06997511190
cobas® **omni** Wash Reagent	06997503190
Solid Waste Bag or Solid Waste Bag with Insert	07435967001 or 08030073001

Additional materials required for the cobas® 6800/8800 Systems

Table 9 Material and consumables for use on **cobas**® 6800/8800 Systems

Material	P/N
Roche Whole Blood Collection Tube	08827907001
cobas® **omni** Processing Plate	05534917001
cobas® **omni** Amplification Plate	05534941001
cobas® **omni** Pipette Tips	05534925001
cobas® **omni** Liquid Waste Container	07094388001
cobas® **omni** Lysis Reagent	06997538190
cobas® **omni** MGP Reagent	06997546190
cobas® **omni** Specimen Diluent	06997511190
cobas® **omni** Wash Reagent	06997503190
Solid Waste Bag	07435967001
Solid Waste Container or Solid Waste Bag With Insert	07094361001 or 08030073001

Instrumentation and software required

The **cobas**® Malaria analysis package for the **cobas**® 5800 System shall be installed on the **cobas**® 5800 System. The x800 Data Manager software for the **cobas**® 5800 System will be provided with the system. The **cobas**® **Synergy** software shall be installed.

The **cobas**® 6800/8800 software and **cobas**® Malaria analysis package shall be installed on the instrument(s). The Instrument Gateway (IG) server will be provided with the system. The **cobas**® **Synergy** software shall be installed, if applicable.

Table 10 Instrumentation

Equipment	**P/N**
cobas® 5800 System	**08707464001**
cobas® 6800 System (Option Moveable)	05524245001 and 06379672001
cobas® 6800 System (Fix)	05524245001 and 06379664001
cobas® 8800 System	05412722001
Sample Supply Module for **cobas**® 6800/8800 Systems	06301037001
Options for pipetting and pooling	**P/N**
cobas® **Synergy** software electronic license (**cobas**® 5800 System)	09311246001
cobas® **Synergy** software electronic license (**cobas**® 6800/8800 Systems)	09311238001
Hamilton MICROLAB® STAR IVD	04640535001
Hamilton MICROLAB® STARlet IVD	04872649001

Refer to the **cobas**® 5800 System User Assistance or the **cobas**® 6800/8800 Systems User Assistance for additional information. Refer to the **cobas**® **Synergy** software User Assistance, for additional information about primary and secondary sample tubes accepted on the instruments.

Note: Contact your local Roche representative for a detailed order list for sample racks, racks for clotted tips and rack trays accepted on the instruments.

Precautions and handling requirements

Warnings and precautions

As with any test procedure, good laboratory practice is essential to the proper performance of this assay. Due to the high sensitivity of this test, care should be taken to keep reagents and amplification mixtures free of contamination.

- For in vitro diagnostic use only.
- All samples should be handled as if infectious, using good laboratory procedures as outlined in Biosafety in Microbiological and Biomedical Laboratories and in the CLSI Document M29-A4.[15,16] Only personnel proficient in handling infectious materials and the use of **cobas**® Malaria and **cobas**® 5800/6800/8800 Systems, and optionally the Hamilton MICROLAB® STAR IVD/STARlet with **cobas**® **Synergy** software should perform this procedure.
- All human-sourced materials should be considered potentially infectious and should be handled with universal precautions. If spillage occurs, immediately disinfect with a freshly prepared solution of 0.6% sodium hypochlorite in distilled or deionized water or follow appropriate site procedures.
- **cobas**® Malaria Control Kit and **cobas**® NHP Negative Control Kit contain plasma derived from human blood. Testing of normal human plasma by PCR methods also showed no detectable Malaria DNA and RNA. No known test method can offer complete assurance that products derived from human blood will not transmit infectious agents.
- The additive in the Roche Whole Blood Collection Tube contains guanidine hydrochloride. Do not allow direct contact between guanidine hydrochloride and sodium hypochlorite (bleach) or other highly reactive reagents such as acids or bases. These mixtures can release a noxious gas. If additive containing guanidine hydrochloride is spilled, clean with suitable laboratory detergent and water. If the spilled additive contains potentially infectious agents, FIRST clean the affected area with laboratory detergent and water, and then with 0.6% sodium hypochlorite.
- The use of sterile disposable pipettes and nuclease-free pipette tips is recommended. Use only supplied or specified required consumables to ensure optimal test performance.
- Closely follow procedures and guidelines provided to ensure that the test is performed correctly. Any deviation from the procedures and guidelines may affect optimal test performance.
- False positive results may occur if carryover of samples is not adequately controlled during sample handling and processing.
- Inform your local competent authority and manufacturer about any serious incidents which may occur when using this assay.

Reagent handling

- Handle all reagents, controls, and samples according to good laboratory practice in order to prevent carryover of samples or controls.
- Before use, visually inspect each reagent cassette, diluent, lysis reagent, and wash reagent to ensure that there are no signs of leakage. If there is any evidence of leakage, do not use that material for testing.
- **cobas**® **omni** Lysis Reagent contains guanidine thiocyanate, a potentially hazardous chemical. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur.
- The additive in the Roche Whole Blood Collection Tube contains guanidine hydrochloride, a potentially hazardous chemical. Avoid contact of this additive with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur.
- **cobas**® Malaria kits, **cobas**® **omni** MGP Reagent, and **cobas**® **omni** Specimen Diluent contain sodium azide as a preservative. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur. If these reagents are spilled, dilute with water before wiping dry.
- Do not allow **cobas**® **omni** Lysis Reagent, which contains guanidine thiocyanate, to contact sodium hypochlorite (bleach) solution. This mixture can produce a highly toxic gas.
- Safety Data Sheets (SDS) are available on request from your local Roche representative.
- Dispose of all materials that have come in contact with samples and reagents in accordance with country, state, and local regulations.

Good laboratory practice

- Do not pipette by mouth.
- Do not eat, drink, or smoke in designated work areas.
- Wear laboratory gloves, laboratory coats, and eye protection when handling samples and reagents. Gloves must be changed between handling samples and **cobas**® Malaria kits and **cobas**® **omni** reagents to prevent contamination. Avoid contaminating gloves when handling samples and controls.
- Wash hands thoroughly after handling samples and kit reagents, and after removing the gloves.
- Thoroughly clean and disinfect all laboratory work surfaces with a freshly prepared solution of 0.6% sodium hypochlorite in distilled or deionized water. Follow by wiping the surface with 70% ethanol.
- If spills occur on the **cobas**® 5800 instrument, follow the instructions in the **cobas**® 5800 System User Assistance to properly clean and decontaminate the surfaces of the instrument(s).
- If spills occur on the **cobas**® 6800/8800 instruments, follow the instructions in the **cobas**® 6800/8800 Systems User Assistance to properly clean and decontaminate the surface of instrument(s).

Sample collection, transport, storage and pooling

Note: Handle all samples and controls as if they are capable of transmitting infectious agents.

- Store all donor samples at specified temperatures.
- Sample stability is affected by elevated temperatures.
- Centrifuge samples at 1000 RCF (relative centrifugal force) for 2 minutes.

Living donor samples

- Whole blood collected in the Roche Whole Blood Collection Tube may be used with **cobas**® Malaria. Follow the sample collection tube manufacturer instructions for handling and centrifugation.
- Whole blood collected in the Roche Whole Blood Collection Tube may be stored for up to 60 days with the following conditions:
    - For storage above 8°C, samples may be stored for 72 hours at up to 25°C, and up to 30°C for 24 hours during the 72 hours.

Other than noted above, samples are stored at 2-8°C. In addition, the Roche Whole Blood Collection Tube may be stored within the first 12 days after collection for up to 12 months at -20°C (± 5°C) with three freeze/thaw cycles. Refer to Figure 1.

Figure 1 Sample storage conditions for samples collected in the Roche Whole Blood Collection Tube



- If the Roche Whole Blood Collection Tube of a donor is not available for testing (e.g., if the tube is damaged or if whole blood was not collected using the Roche Whole Blood Collection Tube), whole blood collected in EDTA anti-coagulant may be used with **cobas**® Malaria.
- Before testing with **cobas**® Malaria 1.1 mL of EDTA whole blood must be **manually transferred** to the Roche Whole Blood Collection Tube.
- Whole blood collected in EDTA may be stored for up to 12 days prior to dilution in the Roche Whole Blood Collection Tube with the following conditions:
    - For storage above 8°C, samples may be stored for 72 hours at up to 25°C, and up to 30°C for 24 hours during the 72 hours.
    - Other than noted above, samples are stored at 2-8°C. Refer to Figure 2.
- After dilution in the whole blood collection tube the tube may be stored for up to 48 hours at 2-25°C.

Other than noted above, following dilution in the Roche Whole Blood Collection Tube, specimens are stable at -20°C (+/- 5°C) for 12 months with 3 freeze/thaws when the specimen is frozen within 48 hours of dilution. Refer to Figure 2.

If samples are to be shipped, they should be packaged and labeled in compliance with applicable country and/or international regulations covering the transport of samples and etiologic agents.

Figure 2 Sample storage conditions for living donor samples collected in EDTA anticoagulant



Instructions for use

Automated sample pipetting and pooling (optional)

cobas® **Synergy** software with the Hamilton MICROLAB® STAR IVD can be used as an optional component of the **cobas**® 5800/6800/8800 Systems for automated pipetting and pooling of aliquots of multiple primary samples into one pooled sample. Refer to the **cobas**® **Synergy** software User Assistance for more information.

Procedural notes

- Do not use **cobas**® Malaria reagents, **cobas**® Malaria Control Kit, **cobas**® NHP Negative Control Kit or **cobas**® **omni** reagents after their expiry dates.
- Do not reuse consumables. They are for one-time use only.
- Refer to the **cobas**® 5800 System User Assistance for proper maintenance of instruments.
- Refer to the **cobas**® Synergy software User Assistance as applicable for details on optional pooling procedures and proper maintenance of instruments.
- Invalid results may be influenced by a number of contributing factors including, but not limited to, sample characteristics, interfering substances and pre-analytical workflows.

Running cobas® Malaria on the cobas® 5800 System

The test procedure is described in detail in the **cobas**® 5800 System User Assistance. Figure 3 below summarizes the procedure. Refer to the **cobas**® **Synergy** software User Assistance as applicable for details on optional pooling procedures.

Figure 3 cobas® Malaria procedure



Running cobas® Malaria on the cobas® 6800/8800 Systems

The test procedure is described in detail in the **cobas**® 6800/8800 Systems User Assistance or refer to the **cobas**® **Synergy** software User Assistance as applicable for details on optional pooling procedures. Figure 4 below summarizes the procedure.

Figure 4 cobas® Malaria procedure



Results

The **cobas**® 5800 or **cobas**® 6800/8800 Systems automatically detect *Plasmodium* nucleic acid simultaneously for the samples and controls.

Quality control and validity of results on the cobas® 5800 System

The **cobas**® 5800 System will be delivered with the default setting of controls (positive and negative) scheduled with every run, but can be configured to a less frequent control schedule, by a Roche service engineer or by contacting Roche customer technical support, based on laboratory procedures and/or local regulations.

- In the **cobas**® 5800 System and/or report, check for flags and their associated results to ensure control validity.
- The associated samples are valid if no flags appear for either control.

Invalidation of results is performed automatically by the **cobas**® 5800 System based on negative or positive control failures.

Control results on cobas® 5800 System

The results of the controls are shown in the **cobas**® 5800 software in the "Controls" app.

- Controls are marked with "Valid" in the column "Control result" if all Targets of the control are reported valid. Controls are marked with 'Invalid' in the column "Control result" if all or one Target of the control are reported invalid.
- Controls marked with 'Invalid' show a flag in the "Flags" column. More information on why the control is reported invalid including flag information will be shown in the detail view.
- If the positive control is invalid, repeat test the positive control and all associated samples. If the negative control is invalid, repeat test both controls and all associated samples.

Table 11 Control flags for negative and positive controls on the **cobas**® 5800 System

Negative Control	**Flag**	**Control Result**	**Interpretation**
(-) C	A flag is shown	Invalid	The entire batch is assigned invalid if the result for the (-) C is invalid.
Positive Control	**Flag**	**Control Result**	**Interpretation**
Malaria (+) C	A flag is shown	Invalid	The entire batch is assigned invalid if the result for the Malaria (+) C is invalid.

If one of the controls is invalid, repeat test the respective control(s) and all associated samples.

Quality control and validity of results on the cobas® 6800/8800 Systems

- One negative control [(–) C] and one positive control [Malaria (+) C] are processed with each batch.
- In the **cobas**® 6800/8800 software and/or report, check for flags and their associated results to ensure the batch validity.
- The batch is valid if no flags appear for both controls.

Invalidation of results is performed automatically by the **cobas**® 6800/8800 software based on negative and positive control failures.

Control flags

Table 12 Control flags for negative and positive controls

Negative Control	**Flag**	**Result**	**Interpretation**
(-) C	Q02	Invalid	The entire batch is assigned invalid if the result for the (-) C is invalid.
Positive Control	**Flag**	**Result**	**Interpretation**
Malaria (+) C	Q02	Invalid	The entire batch is assigned invalid if the result for the Malaria (+) C is invalid.

If the batch is invalid, repeat testing of the entire batch including samples and controls.

Interpretation of results

For a valid batch, check each individual sample for flags in the **cobas**® 5800/6800/8800 software and/or report. The result interpretation should be as follows:

- A valid batch may include both valid and invalid donor sample results dependent on flags obtained for the individual samples.
- Sample results are valid only if the respective positive control and the negative control of the corresponding batch are valid.

Two parameters are measured simultaneously for each sample: *Plasmodium* and the internal control. Final sample results for the **cobas**® Malaria test are reported by the software. In addition to the overall results, individual target results will be displayed in the **cobas**® 5800/6800/8800 software and should be interpreted as follows:

Table 13 Target results for individual target result interpretation

Target results	**Interpretation**
Malaria Non-Reactive	No target signal detected for Plasmodium and IC signal detected.
Malaria Reactive	Target signal detected for Plasmodium and IC signal may be or may not be detected.
Invalid	Target and internal control signal not detected.

If using the **cobas**® **Synergy** software, review of the final result calculation should be performed through the **cobas**® **Synergy** software.

Additional Information for Interpretation of results on the cobas® 5800 System

The results of the samples are shown in the **cobas**® 5800 System. It is recommended to review results in in the **cobas**® Synergy software.

- Samples associated with a valid control batch (as defined by your system control configuration) are shown as 'Valid' in the "Control result" column. Samples associated with a failed control batch are shown as 'Invalid' in the "Control result" column.
- If the associated controls of a sample result are invalid, a specific flag will be added to the sample result as follows:
    - Q05D : Result validation failure because of an invalid positive control
    - Q06D : Result validation failure because of an invalid negative control
- The values in "Results" column for individual sample target result should be interpreted as shown in Table 11 above.
    - The **cobas**® 5800 System will display individual target results. The overall result will be shown only in the result view of the **cobas**® **Synergy** software.
- For more detailed information on sample results and flags refer to the **cobas**® 5800 System User Assistance.

Repeat testing of individual sample(s)

Sample tubes with a final results of Invalid for the target require repeat testing.

Procedural limitations

- **cobas**® Malaria has been evaluated only for use in combination with the **cobas**® Malaria Control Kit, **cobas**® NHP Negative Control Kit, **cobas**® **omni** MGP Reagent, **cobas**® **omni** Lysis Reagent, **cobas**® **omni** Specimen Diluent, and **cobas**® **omni** Wash Reagent for use on the **cobas**® 5800 and **cobas**® 6800/8800 Systems.
- **cobas**® Malaria must only be used with whole blood samples collected with or manually added to the Roche Whole Blood Collection tube.
- Reliable results depend on proper sample collection, storage and handling procedures.
- Detection of *Plasmodium* DNA and RNA is dependent on the number of Malaria infected red blood cells present in the sample and may be affected by sample collection, storage and handling, patient factors (i.e., age, presence of symptoms), stage of infection and pool size.
- Though rare, mutations within the highly conserved regions of a *Plasmodium* genome covered by **cobas**® Malaria, may affect primer and/or probe binding resulting in the failure to detect presence of the *Plasmodium* organism.
- Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to qualify technology differences. Users should follow their own specific policies/procedures.

System equivalency/system comparison

System equivalency of the **cobas**® 5800 System with the **cobas**® 6800/8800 Systems was demonstrated via equivalency studies. The results presented in these Instructions for Use are based on equivalent performance for all systems.

Non-clinical performance evaluation performed on the cobas® 6800/8800 Systems

Key performance characteristics

Limit of Detection (LoD)

Analytical sensitivity was determined for *Plasmodium falciparum, P. malariae, P. vivax, P. ovale and P. knowlesi.*

LoD using whole blood sample prior to lysis

The LoD of **cobas**® Malaria was determined using *Plasmodium falciparum* strain 3D7 infected red blood cells (iRBC) serially diluted in whole blood prior to lysis in the chaotropic reagent.

The stock titer was assigned as percentage parasitemia (*Plasmodium* infected red blood cells per mL, living synchronous ring stage, Giemsa stain).

Three independent dilution series of the infected red blood cell stock were prepared in human whole blood. 1.1 ml aliquots of each concentration were inoculated into a Roche Whole Blood Collection tube and tested by **cobas**® Malaria.

Each dilution series was tested using three lots of **cobas**® Malaria kits with 45 replicates per lot, for a total of 135 replicates per concentration. PROBIT analysis on the data combined across dilution series and reagent lots was used to estimate the 50% and 95% LoD, along with the lower and upper limit of 95% confidence intervals (Table 14). The reactivity rates observed in this LoD study are summarized in Table 15.

Table 14 Results of PROBIT analysis on LoD data for *Plasmodium* iRBCs in human whole blood

Analyte	50% LoD (iRBC/mL)	95% LoD (iRBC/mL)
Plasmodium falciparum	0.6 (0.5 – 0.7)	2.9 (2.4 – 3.8)

Table 15 Reactivity rates summary for *Plasmodium falciparum*

***Plasmodium falciparum* (iRBC/mL)**	**Number reactive**	**Number of valid replicates**	**% Reactive**	**95% Lower confidence bound (one-sided)**
10.0	135	135	100.0%	97.8%
5.0	134	135	99.3%	96.5%
2.5	126	135	93.3%	88.7%
1.0	85	135	63.0%	55.6%
0.5	59	135	43.7%	36.5%
0	0	135	0.0%	0.0%

LoD using Roche Secondary Standards

The LoD of **cobas**® Malaria was determined using in-house Secondary Standards for *Plasmodium falciparum* strain 3D7, *Plasmodium vivax* ATCC 30073 strain NICA and *Plasmodium knowlesi* strain A1-H.1. Secondary standards are infected red blood cells quantitated prior to resuspension in the pre-analytic chaotropic reagent and stored frozen prior to testing.

Secondary Standards were used to prepare 3 independent dilution series using a whole blood chaotropic reagent mixture, simulating the final sample. The dilution series were tested across three reagent lots using 65-66 replicates per lot, for a total of 197-198 replicates per concentration. PROBIT analysis on the data combined across dilution series and reagent lots was used to estimate the 50% and 95% LoD reported as iRBC/mL of whole blood, along with the lower and upper limit of 95% confidence intervals (Table 16). The reactivity rates observed in this LoD study are summarized in Table 17 to Table 19.

Table 16 Results of PROBIT analysis on LoD data collected with lysed *Plasmodium* iRBCs diluted in whole blood/chaotropic reagent mixture

Analyte	**50% LoD** (iRBC/mL)	**95% LoD** (iRBC/mL)
Plasmodium falciparum	0.013 (0.011 – 0.014)	0.058 (0.049 – 0.071)
Plasmodium vivax	0.003 (0.002 – 0.003)	0.012 (0.010 – 0.015)
Plasmodium knowlesi	0.009 (0.008 – 0.011)	0.044 (0.037 – 0.054)

Table 17 Reactivity rates summary for *Plasmodium falciparum* Secondary Standard

***Plasmodium falciparum* (iRBC/mL)**	**Number reactive**	**Number of valid replicates**	**% Reactive**	**95% Lower confidence bound (one-sided)**
0.130	197	197	100.0%	98.5%
0.052	187	198	94.4%	91.0%
0.026	151	198	76.3%	70.8%
0.013	94	198	47.5%	41.4%
0.007	60	198	30.3%	24.9%
0	0	198	0.0%	0.0%

Table 18 Reactivity rates summary for *Plasmodium vivax* Secondary Standard

Plasmodium vivax **(iRBC/mL)**	**Number reactive**	**Number of valid replicates**	**% Reactive**	**95% Lower confidence bound (one-sided)**
0.033	198	198	100.0%	98.5%
0.013	194	198	98.0%	95.4%
0.007	158	198	79.8%	74.5%
0.003	111	198	56.1%	50.0%
0.002	77	198	38.9%	33.1%
0	0	198	0.0%	0.0%

Table 19 Reactivity rates summary for *Plasmodium knowlesi* Secondary Standard

Plasmodium knowlesi **(iRBC/mL)**	**Number reactive**	**Number of valid replicates**	**% Reactive**	**95% Lower confidence bound (one-sided)**
0.195	198	198	100.0%	98.5%
0.078	196	198	99.0%	96.9%
0.039	186	198	94.0%	90.4%
0.020	153	198	77.3%	71.8%
0.010	108	198	54.6%	48.5%
0	0	198	0.0%	0.0%

LoD using Armored RNA

The LoD of **cobas**® Malaria for the 5 *Plasmodium* species was also determined using armored RNA sequences in **cobas**® **omni** Specimen Diluent. The armored RNA sequences correspond to the target regions of the 18S ribosomal RNA of *Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium ovale and Plasmodium knowlesi*.

One dilution series in **cobas**® **omni** Specimen Diluent was prepared for each material and tested using three different lots of **cobas**® Malaria kits with 23-24 replicates per lot, for a total of 71-72 replicates per concentration. PROBIT analysis on the data combined across reagent lots was used to estimate the 50% and 95% LoD, along with the lower and upper limit of 95% confidence intervals (Table 20). The reactivity rates observed in this LoD study are summarized in Table 21 to Table 25.

Table 20 Results of PROBIT analysis on LoD data collected with *Plasmodium* armored RNA in **cobas**® **omni** Specimen Diluent

Analyte	50% LoD (armored particles/mL)	95% LoD (armored particles/mL)
Plasmodium falciparum	8.2 (6.8 – 9.5)	27.9 (22.5 – 38.5)
Plasmodium malariae	9.0 (7.5 – 10.4)	32.2 (25.8 – 44.7)
Plasmodium vivax	8.2 (6.7 – 9.7)	33.1 (26.3 – 46.5)
Plasmodium ovale	9.5 (7.5 – 11.4)	59.0 (44.1 – 90.3)
Plasmodium knowlesi	6.6 (5.2 – 7.8)	23.7 (18.9 – 33.6)

Table 21 Reactivity rates summary for *Plasmodium falciparum* armored RNA in **cobas**® **omni** Specimen Diluent

Plasmodium falciparum **(armored particles/mL)**	Number reactive	Number of valid replicates	% Reactive	95% Lower confidence bound (one-sided)
100	72	72	100.0%	95.9%
50	72	72	100.0%	95.9%
25	66	72	91.7%	84.2%
12	50	72	69.4%	59.3%
6	25	72	34.7%	25.4%
0	0	72	0.0%	0.0%

Table 22 Reactivity rates summary for *Plasmodium malariae* armored RNA in **cobas**® **omni** Specimen Diluent

Plasmodium malariae **(armored particles/mL)**	Number reactive	Number of valid replicates	% Reactive	95% Lower confidence bound (one-sided)
100	72	72	100.0%	95.9%
50	72	72	100.0%	95.9%
25	64	71	90.1%	82.3%
12	42	72	58.3%	48.0%
6	25	72	34.7%	25.4%
0	0	72	0.0%	0.0%

Table 23 Reactivity rates summary for *Plasmodium vivax* armored RNA in **cobas**® **omni** Specimen Diluent

Plasmodium vivax **(armored particles/mL)**	**Number reactive**	**Number of valid replicates**	**% Reactive**	**95% Lower confidence bound (one-sided)**
100	72	72	100.0%	95.9%
50	71	72	98.6%	93.6%
25	63	72	87.5%	79.2%
12	52	72	72.2%	62.2%
6	24	72	33.3%	24.2%
0	0	72	0.0%	0.0%

Table 24 Reactivity rates summary for *Plasmodium ovale* armored RNA in **cobas**® **omni** Specimen Diluent

Plasmodium ovale **(armored particles/mL)**	**Number reactive**	**Number of valid replicates**	**% Reactive**	**95% Lower confidence bound (one-sided)**
100	72	72	100.0%	95.9%
50	69	72	95.8%	95.9%
25	52	72	72.2%	62.2%
12	41	72	56.9%	46.6%
6	28	72	38.9%	29.2%
0	0	72	0.0%	0.0%

Table 25 Reactivity rates summary for *Plasmodium knowlesi* armored RNA in **cobas**® **omni** Specimen Diluent

Plasmodium knowlesi **(armored particles/mL)**	**Number reactive**	**Number of valid replicates**	**% Reactive**	**95% Lower confidence bound (one-sided)**
100	72	72	100.0%	95.9%
50	72	72	100.0%	95.9%
25	69	72	95.8%	89.6%
12	54	72	75.0%	65.2%
6	34	72	47.2%	37.1%
0	0	71	0.0%	0.0%

Repeatability

The repeatability of **cobas**® Malaria was determined using the following standards:

- Roche Secondary Standard for *Plasmodium falciparum*
- Roche Secondary Standard for *Plasmodium vivax*
- Roche Secondary Standard for *Plasmodium knowlesi*

For each *Plasmodium* species, 3 panel members consisting of whole blood (WB) diluted in **cobas**® PCR media (CPM) spiked at three different concentration levels (~2.5x LoD, ~1x LoD and ~0.5x LoD), were used for analysis.

Testing was performed for the following variability components:

- day-to-day variability over 3 days
- lot-to-lot variability using 3 different reagent lots of the **cobas**® Malaria test
- instrument-to-instrument variability using 3 different **cobas**® 8800 Systems

Approximately 21 replicates were tested with each of the 3 panels for a total of 63 replicates with each reagent lot. All valid repeatability data were evaluated by calculating the percentage of reactive test results for each concentration level across all variable components.

The limits of two-sided 95% Confidence Intervals for each reactive rate were calculated for each of the three levels of each species tested across 3 days, 3 reagent lots, and 3 **cobas**® 8800 Systems. The **cobas**® Malaria test is repeatable over multiple days, reagent lots and instruments. The results from reagent lot-to-lot variability are summarized in Table 26.

Table 26 cobas® Malaria test reagent lot-to-lot repeatability summary

Species	Concentration	Reagent lot	% Reactive (reactive/valid replicates)	Lower limit of 95% confidence interval	Upper limit of 95% confidence interval
Plasmodium falciparum	~2.5 x LoD	1	100.0% (66/66)	94.6%	100.0%
		2	100.0% (66/66)	94.6%	100.0%
		3	100.0% (65/65)	94.5%	100.0%
	~1 x LoD	1	98.5% (65/66)	91.8%	100.0%
		2	90.9% (60/66)	81.3%	96.6%
		3	93.9% (62/66)	85.2%	98.3%
	~0.5 x LoD	1	72.7% (48/66)	60.4%	83.0%
		2	74.2% (49/66)	62.0%	84.2%
		3	81.8% (54/66)	70.4%	90.2%
Plasmodium vivax	~2.5 x LoD	1	100.0% (66/66)	94.6%	100.0%
		2	100.0% (66/66)	94.6%	100.0%
		3	100.0% (66/66)	94.6%	100.0%
	~1 x LoD	1	97.0% (64/66)	89.5%	99.6%
		2	97.0% (64/66)	89.5%	99.6%

Species	Concentration	Reagent lot	% Reactive (reactive/valid replicates)	Lower limit of 95% confidence interval	Upper limit of 95% confidence interval
		3	100.0% (66/66)	94.6%	100.0%
	~0.5 x LoD	1	78.8% (52/66)	67.0%	87.9%
		2	78.8% (52/66)	67.0%	87.9%
		3	81.8% (54/66)	70.4%	90.2%
Plasmodium knowlesi	~2.5 x LoD	1	100% (66/66)	94.6%	100.0%
		2	98.5% (65/66)	91.8%	100.0%
		3	98.5% (65/66)	91.8%	100.0%
	~1 x LoD	1	97.0% (64/66)	89.5%	99.6%
		2	90.9% (60/66)	81.3%	96.6%
		3	93.9% (62/66)	85.2%	98.3%
	~0.5 x LoD	1	77.3% (51/66)	65.3%	86.7%
		2	86.4% (57/66)	75.7%	93.6%
		3	68.2% (45/66)	55.6%	79.1%

Genotype verification

The ability of **cobas**® Malaria to detect 5 species of *Plasmodium* was also shown by testing a total of 10 unique clinical samples each for *Plasmodium falciparum, malariae, vivax* and *ovale*, and the in-house Secondary Standard for *Plasmodium knowlesi strain A1-H.1*. Each clinical sample was tested as 1 replicate neat and 1 replicate after dilution in *Plasmodium* negative human whole blood to approximately 3 x LoD of **cobas**® Malaria. The *Plasmodium knowlesi* standard was tested as 1 replicate each after dilution to approximately 3 x LoD in 10 *Plasmodium* negative human whole blood samples. All samples and cultures were detected neat and at approximately 3 x LoD.

Sensitivity for Clinical Samples

The clinical sensitivity of **cobas**® Malaria was evaluated in-house using 100 individual clinical samples (61 *P. falciparum* and 39 *P. vivax*) that were known to be *Plasmodium*-positive based on microscopy testing. All samples were quantified traceable to the *Plasmodium falciparum* or *Plasmodium vivax* Roche Secondary Standards. Each clinical sample was tested singly after dilution in a mixture of *Plasmodium* negative human whole blood and chaotropic reagent to approximately 5 x LoD and 3 x LoD of **cobas**® Malaria (Table 27). All samples were detected as Reactive.

Table 27 Clinical Sensitivity for *Plasmodium falciparum* and *vivax*

Species	Concentration	Number Reactive/ Total Samples	% Sensitivity (95% CI)
P. falciparum	~ 5x LoD	61/61	**100%** (94.1% - 100%)
P. falciparum	~3x LoD	61/61	**100%** (94.1% - 100%)
P. vivax	~ 5x LoD	39/39	**100%** (91.0% - 100%)
P. vivax	~3x LoD	39/39	**100%** (91.0% - 100%)

Note: CI = two-sided Clopper-Pearson (exact) binomial confidence interval

Analytical specificity

Analytical specificity – cross reactivity

The analytical specificity of **cobas**® Malaria was evaluated for cross-reactivity with 16 microorganisms at 10^5 - 10^6 copies, genome copies, cells, CFU or IU/mL, which included 6 viral isolates, 1 parasite, 8 bacterial strains and 1 yeast isolate (Table 28). The microorganisms (up to 5 clinical samples and/or 1 culture each) and were added to *Plasmodium*-negative human whole blood and tested with and without *Plasmodium* added to a concentration of approximately 3 x LoD of **cobas**® Malaria. The tested microorganisms do not cross-react or interfere with **cobas**® Malaria.

Table 28 Microorganisms tested for analytical specificity

Anaplasma phagocytophilum	*Candida albicans*	Parvovirus B19
Babesia microti	Chikungunya Virus	*Staphylococcus aureus*
Borrelia burgdorferi	*Cutibacterium acnes*	*Staphylococcus epidermidis*
Borrelia hermsii	Hepatitis B Virus	West Nile Virus
Borrelia parkerii	Hepatitis C Virus	-
Borrelia recurrentis	Human Immunodeficiency Virus	-

Analytical specificity – interfering substances

Endogenous interference substances

Whole blood samples with abnormally high levels of triglycerides (33 g/L), hemoglobin (≥ 200 g/L), unconjugated bilirubin (684 µmol/L), albumin (60 g/L), and human DNA (2 mg/L) were tested with and without *Plasmodium falciparum* added to a concentration of approximately 3 x LoD of **cobas**® Malaria. Samples containing these endogenous substances did not cross-react or interfere with the **cobas**® Malaria.

Exogenous interference substances

Plasmodium-negative human whole blood samples containing abnormally high concentrations of drugs (Table 29) were tested with and without P*lasmodium* added to a concentration of 3 x LoD of **cobas**® Malaria. These exogenous substances did not cross-react or interfere with the **cobas**® Malaria.

Table 29 Concentrations of the drugs added into whole blood

Name of drug tested	**Concentration**
Acetaminophen	1324 µmol/L
Acetylsalicylic Acid	3620 µmol/L
Ascorbic Acid	342 µmol/L
Atenolol	33.8 µmol/L
Atorvastatin	1.34 µmol/L
Atovaquone	1227 µmol/L
Azithromycin	15.3 µmol/L
Fluoxetine	11.2 µmol/L

Ibuprofen	2425 µmol/L
Loratadine	0.78 µmol/L
Naproxen	2170 µmol/L
Paroxetine	3.63 µmol/L
Phenylephrine HCl	491 µmol/L
Sertraline	3.03 µmol/L

Whole System Failure

The whole system failure rate of **cobas**® Malaria was determined by testing 100 replicates of whole blood spiked with *Plasmodium falciparum* at a target concentration of approximately 3 x LoD. Before testing with **cobas**® Malaria each panel member was diluted in the Roche Whole Blood Collection Tube. The results of this study determined that all replicates were reactive, resulting in a whole system failure rate of 0%. The two-sided 95% exact confidence interval was 0% for the lower bound and 3.6% for the upper bound [0%: 3.6%].

Clinical performance evaluation

Clinical sensitivity

The clinical sensitivity of **cobas**® Malaria was evaluated using 417 individual samples (237 clinical samples (*P. falciparum*, *P. vivax*, and *P. malariae*) and 180 contrived samples (*P. falciparum*, *P. malariae*, *P. vivax*, *P. ovale*, and *P. knowlesi*) that were known to be *Plasmodium*-positive based on NAT testing. The study was conducted at three testing laboratories, with each site testing approximately one third of the samples, both neat and diluted 1:6 (to simulate pools of 6), using three different lots of **cobas**® Malaria.

The clinical sensitivity of **cobas**® Malaria with neat samples in this study was 100% (417/417; 95% two-sided Clopper-Pearson (exact) binomial Confidence Interval (CI): 99.1% to 100%) (Table 30) and with samples diluted 1:6 was 99.8% (416/417; 95% CI: 98.7% to 99.99%) (Table 31). For the diluted sample with a non-reactive **cobas**® Malaria result, the Ct value from **cobas**® Malaria testing of the neat sample is consistent with a concentration of approximately 3 x limit of detection (LoD). This would result in a concentration of ~0.5 x LoD when diluted 1:6, with a Poisson predicted reactivity rate of approximately 78%.

Table 30 Clinical sensitivity of known *Plasmodium*-positive neat samples

Dilution	Sample Type	Species	Total Known *Plasmodium*-Positive Samples	Number Reactive	Sensitivity Estimate	95% Exact CI
Neat	Overall	n/a	417	417	100.0%	(99.1%, 100.0%)
Neat	Clinical/Contrived	*P. falciparum*	154	154	100.0%	(97.6%, 100.0%)
Neat	Clinical/Contrived	*P. malariae*	37	37	100.0%	(90.5%, 100.0%)
Neat	Clinical/Contrived	*P. vivax*	154	154	100.0%	(97.6%, 100.0%)
Neat	Contrived	*P. ovale*	36	36	100.0%	(90.3%, 100.0%)
Neat	Contrived	*P. knowlesi*	36	36	100.0%	(90.3%, 100.0%)

Note: CI = two-sided Clopper-Pearson (exact) binomial confidence interval, n/a = not applicable.

Table 31 Clinical sensitivity of known *Plasmodium*-positive diluted 1:6 samples

Dilution	Sample Type	Species	Total Known *Plasmodium*-Positive Samples	Number Reactive	Sensitivity Estimate	95% Exact CI
1:6	Overall	n/a	417	416	99.8%	(98.7%, 99.99%)
1:6	Clinical/Contrived	*P. falciparum*	154	153	99.4%	(96.4%, 99.98%)
1:6	Clinical/Contrived	*P. malariae*	37	37	100.0%	(90.5%, 100.0%)
1:6	Clinical/Contrived	*P. vivax*	154	154	100.0%	(97.6%, 100.0%)
1:6	Contrived	*P. ovale*	36	36	100.0%	(90.3%, 100.0%)
1:6	Contrived	*P. knowlesi*	36	36	100.0%	(90.3%, 100.0%)

Note: CI = two-sided Clopper-Pearson (exact) binomial confidence interval, n/a = not applicable.

Clinical specificity

The clinical specificity of **cobas**® Malaria was evaluated using blood donations (approximately 1 mL of whole blood collected in a Roche Whole Blood Collection Tube) screened at three external laboratory sites. Four different **cobas**® Malaria reagent lots were used in this study. Clinical specificity of **cobas**® Malaria was calculated as the percentage (95% two-sided CI) of *Plasmodium* status-negative donors who had **cobas**® Malaria non-reactive results. A total of 20,187 evaluable donations were tested as individual samples, 67,612 evaluable donations were tested in pools of six (PP6), and 159 evaluable donations from donors deferred from donating blood due to their responses to questions about malaria risk were tested as individual samples.

Individual testing results

Table 32 shows the comparison of **cobas**® Malaria results and donation status for 20,187 evaluable donations from which whole blood samples were tested individually.

Table 32 Comparison of **cobas**® Malaria results with donation status – individual donation testing

cobas® Malaria Result	**Donation Status* Positive n (%)**	**Donation Status* Negative n (%)**	**Donation Status* Unresolved n (%)**	**Total N**
Reactive	0 (0.000)	0 (0.000)	0 (0.000)	0
Non-Reactive	0 (0.000)	20,187 (100.000)	0 (0.000)	20,187
Total	0	20,187	0	20,187

Note: Only evaluable donations are included in this summary table.

* Donation Status was assigned based on the testing reactivity pattern observed on the index donation (initial and additional index testing) and/or based on follow-up study results.

The clinical specificity for **cobas**® Malaria for donations tested individually was 100% (20,187/20,187; 95% CI: 99.982% to 100%) (Table 33).

Table 33 Clinical specificity of **cobas**® Malaria – individual donation testing

Parameter	**Total Number of Status-Negative Donations**	**cobas**® **Malaria Reactive**	**cobas**® **Malaria Non-Reactive**	**Estimate in Percent (95% Exact CI)**
Clinical Specificity	20,187	0	20,187	100.000 (99.982, 100.000)

Note: Only evaluable donations are included in this summary table. CI = two-sided Clopper-Pearson (exact) binomial confidence interval.

For donor samples that were tested individually, 339 (99.4%) valid **cobas**® Malaria batches yielded 20,187 (98.92%) valid results. Overall, 99.50% of donations tested individually contributed valid results after initial testing and retesting, if performed, in the study. Retesting was not performed for 0.43% of donations tested individually.

Pools of 6 testing results

Table 34 shows the comparison of **cobas**® Malaria results and donation status for 67,612 evaluable donations from which whole blood samples were tested in PP6.

Table 34 Comparison of **cobas**® Malaria results with donation status - pools of 6 (donation level)

cobas® Malaria Result	Donation Status* Positive n (%)	Donation Status* Negative n (%)	Donation Status* Unresolved n (%)	Total N
Reactive	0 (0.000)	0 (0.000)	0 (0.000)	0
Non-Reactive	0 (0.000)	67,612 (100.000)	0 (0.000)	67,612
Total	0	67,612	0	67,612

Note: Only evaluable donations are included in this summary table.

* Donation Status was assigned based on the testing reactivity pattern observed on the index donation (initial and additional index testing) and/or based on follow-up study results.

The clinical specificity for **cobas**® Malaria for donations tested in PP6 was 100% (67,612/67,612; 95% CI: 99.995% to 100%) (Table 35).

Table 35 Clinical specificity of **cobas**® Malaria - donations tested in pools of 6 only (donation level)

Parameter	Total Number of Status-Negative Donations	cobas® Malaria Reactive	cobas® Malaria Non-Reactive	Estimate in Percent (95% Exact CI)
Clinical Specificity	67,612	0	67,612	100.000 (99.995, 100.000)

Note: Only evaluable donations are included in this summary table. CI = two-sided Clopper-Pearson (exact) binomial confidence interval.

Table 36 summarizes the pool reactivity for the 11,291 qualifying PP6. All 11,291 (100%) pools were non-reactive on **cobas**® Malaria. The overall pool specificity of **cobas**® Malaria was 100% (11,291/11,291 pools; 95% CI: 99.967 to 100%).

Table 36 Pool reactivity in volunteer blood donors

Category	Number of Pools	Percentage of Pools Tested
Total Pools tested [a]	11,291	100.0
Non Reactive pools [b]	11,291	100.0
Non-reactive pools with all donations status-negative	11,291	100.0
Non-reactive pools with at least one status-positive donation	0	0
Non-reactive pools without positive donation but had at least one status-unresolved donation	0	0
Reactive pools [b]	0	0
Reactive pools with at least one status-positive donation	0	0
Reactive pools with donations status-negative (false reactive pools)	0	0
Reactive pools without positive donation but had at least one status-unresolved donation	0	0

[a] Note: 135/11,291 pools had < 6 donations.

[b] Donation Status was assigned based on the testing reactivity pattern observed on the index donation (initial and additional index testing) and/or based on follow-up study results.

For donor samples that were tested in PP6, a total of 355 (98.6%) valid **cobas**® Malaria batches yielded 11,291 (98.31%) valid pool results and 1 valid secondary pool of 1 result. Overall, 99.82% of donations tested in PP6 contributed valid results after initial testing and retesting, if performed, in the study. Retesting was not performed for 0.15% of donations tested in PP6.

Deferred Donors

Table 37 shows the comparison of **cobas**® Malaria results and donation status for 159 evaluable donations from deferred donors that were tested individually. No deferred donors were confirmed positive for *Plasmodium* infection.

Table 37 Comparison of **cobas**® Malaria results with donation status – deferred donors

cobas® Malaria Result	Donation Status* Positive n (%)	Donation Status* Negative n (%)	Donation Status* Unresolved n (%)	Total N
Reactive	0 (0.000)	0 (0.000)	0 (0.000)	0
Non-Reactive	0 (0.000)	159 (100.000)	0 (0.000)	159
Total	0	159	0	159

Note: Only evaluable donations are included in this summary table.

* Donation Status was assigned based on the testing reactivity pattern observed on the index donation (initial and additional index testing) and/or based on follow-up study results.

Reproducibility

The reproducibility of **cobas**® Malaria was established by testing a 16-member panel composed of one negative panel member and fifteen samples positive for one of each of five *Plasmodium* species (*P. falciparum, P. malariae, P. vivax, P. ovale, and P. knowlesi*) at three different concentrations (approximately 0.5 x, 1-2 x, and approximately 3 x the LoD **cobas**® Malaria for each of the five *Plasmodium* species).

Operators at each of three sites performed five days of testing with each of three lots of **cobas**® Malaria reagents and two valid panel runs (i.e., two batches, each batch composed of one panel and two independent controls) per day were completed to yield up to 270 tests per panel member of *Plasmodium* species at each of the three concentrations.

All valid batches and test results were analyzed by calculating the percentage of reactive test results for each panel member [Table 38 (*P. falciparum*), Table 39 (*P. malariae*), Table 40 (*P. vivax*), Table 41 (*P. ovale*) and Table 42 (*P. knowlesi*)]. This study demonstrated that **cobas**® Malaria for use on the **cobas**® 6800/8800 Systems shows reproducible performance across the variables assessed (lot, site, day, batch, and within batch) for detecting *Plasmodium*.

Table 38 Test results summarized by site, lot, day, and batch (positive panel members) – *Plasmodium falciparum*

Plasmodium falciparum **Concentration**	**Site ID**	**Site % Reactive Results**	**Lot ID**	**Lot % Reactive Results**	**Day ID**	**Day % Reactive Results**	**Batch ID**	**Batch % Reactive Results**
~0.5 x LoD	1	80.0% (72/90)	1	95.6% (86/90)	1	83.3% (45/54)	1	82.2% (111/135)
~0.5 x LoD	2	83.3% (75/90)	2	70.0% (63/90)	2	79.6% (43/54)	2	87.4% (118/135)
~0.5 x LoD	3	91.1% (82/90)	3	88.9% (80/90)	3	88.9% (48/54)	-	-
~0.5 x LoD	-	-	-	-	4	81.5% (44/54)	-	-
~0.5 x LoD	-	-	-	-	5	90.7% (49/54)	-	-
1-2 x LoD	1	100.0% (90/90)	1	100.0% (90/90)	1	100.0% (54/54)	1	100.0% (135/135)
1-2 x LoD	2	100.0% (90/90)	2	100.0% (90/90)	2	100.0% (54/54)	2	100.0% (135/135)
1-2 x LoD	3	100.0% (90/90)	3	100.0% (90/90)	3	100.0% (54/54)	-	-
1-2 x LoD	-	-	-	-	4	100.0% (54/54)	-	-
1-2 x LoD	-	-	-	-	5	100.0% (54/54)	-	-
~3 x LoD	1	100.0% (90/90)	1	100.0% (90/90)	1	100.0% (54/54)	1	100.0% (135/135)
~3 x LoD	2	100.0% (90/90)	2	100.0% (90/90)	2	100.0% (54/54)	2	100.0% (135/135)
~3 x LoD	3	100.0% (90/90)	3	100.0% (90/90)	3	100.0% (54/54)	-	-
~3 x LoD	-	-	-	-	4	100.0% (54/54)	-	-
~3 x LoD	-	-	-	-	5	100.0% (54/54)	-	-

Note: LoD = limit of detection.

Table 39 Test results summarized by site, lot, day, and batch (positive panel members) – *Plasmodium malariae*

Plasmodium malariae **Concentration**	**Site ID**	**Site % Reactive Results**	**Lot ID**	**Lot % Reactive Results**	**Day ID**	**Day % Reactive Results**	**Batch ID**	**Batch % Reactive Results**
~0.5 x LoD	1	74.4% (67/90)	1	88.9% (80/90)	1	72.2% (39/54)	1	79.3% (107/135)
~0.5 x LoD	2	78.9% (71/90)	2	60.0% (54/90)	2	81.5% (44/54)	2	76.3% (103/135)
~0.5 x LoD	3	80.0% (72/90)	3	84.4% (76/90)	3	75.9% (41/54)	-	-
~0.5 x LoD	-	-	-	-	4	85.2% (46/54)	-	-
~0.5 x LoD	-	-	-	-	5	74.1% (40/54)	-	-
1-2 x LoD	1	96.6% (86/89)	1	100.0% (90/90)	1	98.1% (53/54)	1	97.8% (132/135)
1-2 x LoD	2	100.0% (90/90)	2	94.4% (85/90)	2	100.0% (54/54)	2	97.8% (131/134)
1-2 x LoD	3	96.7% (87/90)	3	98.9% (88/89)	3	98.1% (53/54)	-	-
1-2 x LoD	-	-	-	-	4	96.3% (52/54)	-	-
1-2 x LoD	-	-	-	-	5	96.2% (51/53)	-	-
~3 x LoD	1	100.0% (90/90)	1	100.0% (90/90)	1	100.0% (54/54)	1	100.0% (135/135)
~3 x LoD	2	100.0% (90/90)	2	100.0% (90/90)	2	100.0% (54/54)	2	100.0% (135/135)
~3 x LoD	3	100.0% (90/90)	3	100.0% (90/90)	3	100.0% (54/54)	-	-
~3 x LoD	-	-	-	-	4	100.0% (54/54)	-	-
~3 x LoD	-	-	-	-	5	100.0% (54/54)	-	-

Note: LoD = limit of detection.

Table 40 Test results summarized by site, lot, day, and batch (positive panel members) – *Plasmodium vivax*

Plasmodium vivax **Concentration**	**Site ID**	**Site % Reactive Results**	**Lot ID**	**Lot % Reactive Results**	**Day ID**	**Day % Reactive Results**	**Batch ID**	**Batch % Reactive Results**
~0.5 x LoD	1	90.0% (81/90)	1	96.7% (87/90)	1	96.3% (52/54)	1	91.9% (124/135)
~0.5 x LoD	2	93.3% (84/90)	2	86.7% (78/90)	2	87.0% (47/54)	2	94.1% (127/135)
~0.5 x LoD	3	95.6% (86/90)	3	95.6% (86/90)	3	96.3% (52/54)	-	-
~0.5 x LoD	-	-	-	-	4	92.6% (50/54)	-	-
~0.5 x LoD	-	-	-	-	5	92.6% (50/54)	-	-
1-2 x LoD	1	100.0% (90/90)	1	100.0% (90/90)	1	100.0% (54/54)	1	100.0% (134/134)
1-2 x LoD	2	100.0% (89/89)	2	100.0% (89/89)	2	100.0% (54/54)	2	100.0% (135/135)
1-2 x LoD	3	100.0% (90/90)	3	100.0% (90/90)	3	100.0% (53/53)	-	-
1-2 x LoD	-	-	-	-	4	100.0% (54/54)	-	-
1-2 x LoD	-	-	-	-	5	100.0% (54/54)	-	-
~3 x LoD	1	100.0% (89/89)	1	100.0% (89/89)	1	100.0% (54/54)	1	100.0% (134/134)
~3 x LoD	2	100.0% (90/90)	2	100.0% (90/90)	2	100.0% (54/54)	2	100.0% (135/135)
~3 x LoD	3	100.0% (90/90)	3	100.0% (90/90)	3	100.0% (53/53)	-	-
~3 x LoD	-	-	-	-	4	100.0% (54/54)	-	-
~3 x LoD	-	-	-	-	5	100.0% (54/54)	-	-

Note: LoD = limit of detection.

Table 41 Test results summarized by site, lot, day, and batch (positive panel members) – *Plasmodium ovale*

Plasmodium ovale **Concentration**	**Site ID**	**Site % Reactive Results**	**Lot ID**	**Lot % Reactive Results**	**Day ID**	**Day % Reactive Results**	**Batch ID**	**Batch % Reactive Results**
~0.5 x LoD	1	78.9% (71/90)	1	90.0% (81/90)	1	75.9% (41/54)	1	74.1% (100/135)
~0.5 x LoD	2	73.3% (66/90)	2	55.6% (50/90)	2	77.8% (42/54)	2	82.2% (111/135)
~0.5 x LoD	3	82.2% (74/90)	3	88.9% (80/90)	3	85.2% (46/54)	-	-
~0.5 x LoD	-	-	-	-	4	79.6% (43/54)	-	-
~0.5 x LoD	-	-	-	-	5	72.2% (39/54)	-	-
1-2 x LoD	1	100.0% (90/90)	1	100.0% (90/90)	1	100.0% (54/54)	1	99.3% (134/135)
1-2 x LoD	2	98.9% (89/90)	2	98.9% (89/90)	2	98.1% (53/54)	2	100.0% (135/135)
1-2 x LoD	3	100.0% (90/90)	3	100.0% (90/90)	3	100.0% (54/54)	-	-
1-2 x LoD	-	-	-	-	4	100.0% (54/54)	-	-
1-2 x LoD	-	-	-	-	5	100.0% (54/54)	-	-
~3 x LoD	1	100.0% (90/90)	1	100.0% (90/90)	1	100.0% (54/54)	1	100.0% (135/135)
~3 x LoD	2	100.0% (90/90)	2	100.0% (90/90)	2	100.0% (54/54)	2	100.0% (135/135)
~3 x LoD	3	100.0% (90/90)	3	100.0% (90/90)	3	100.0% (54/54)	-	-
~3 x LoD	-	-	-	-	4	100.0% (54/54)	-	-
~3 x LoD	-	-	-	-	5	100.0% (54/54)	-	-

Note: LoD = limit of detection.

Table 42 Test results summarized by site, lot, day, and batch (positive panel members) – *Plasmodium knowlesi*

Plasmodium knowlesi **Concentration**	**Site ID**	**Site % Reactive Results**	**Lot ID**	**Lot % Reactive Results**	**Day ID**	**Day % Reactive Results**	**Batch ID**	**Batch % Reactive Results**
~0.5 x LoD	1	81.1% (73/90)	1	84.4% (76/90)	1	85.2% (46/54)	1	78.5% (106/135)
~0.5 x LoD	2	81.1% (73/90)	2	74.4% (67/90)	2	74.1% (40/54)	2	84.4% (114/135)
~0.5 x LoD	3	82.2% (74/90)	3	85.6% (77/90)	3	83.3% (45/54)	-	-
~0.5 x LoD	-	-	-	-	4	81.5% (44/54)	-	-
~0.5 x LoD	-	-	-	-	5	83.3% (45/54)	-	-
1-2 x LoD	1	100.0% (90/90)	1	100.0% (90/90)	1	100.0% (54/54)	1	100.0% (135/135)
1-2 x LoD	2	100.0% (90/90)	2	100.0% (90/90)	2	100.0% (54/54)	2	100.0% (135/135)
1-2 x LoD	3	100.0% (90/90)	3	100.0% (90/90)	3	100.0% (54/54)	-	-
1-2 x LoD	-	-	-	-	4	100.0% (54/54)	-	-
1-2 x LoD	-	-	-	-	5	100.0% (54/54)	-	-
~3 x LoD	1	100.0% (90/90)	1	100.0% (90/90)	1	100.0% (54/54)	1	100.0% (135/135)
~3 x LoD	2	100.0% (90/90)	2	100.0% (90/90)	2	100.0% (54/54)	2	100.0% (135/135)
~3 x LoD	3	100.0% (90/90)	3	100.0% (90/90)	3	100.0% (54/54)	-	-
~3 x LoD	-	-	-	-	4	100.0% (54/54)	-	-
~3 x LoD	-	-	-	-	5	100.0% (54/54)	-	-

Note: LoD = limit of detection.

Asymptomatic population in an endemic area

The positive percent agreement (PPA) of **cobas**® Malaria results with microscopy was evaluated testing whole blood samples collected from 199 healthy individuals from a malaria-endemic region. All samples were collected in Nigeria in August 2021 [41 (20.6%)] and September 2021 [158 (79.4%)]. Alternate NAT (ALT NAT), microscopy, antigen and antibody results were used to determine the status of each specimen.

Of the 199 evaluable samples from subjects, 4 (2.0%; 4/199) were reactive with **cobas**® Malaria and positive on microscopy for *P. falciparum* and were classified as status-positive (current infection). The PPA was 100% (4/4; 95% CI: 51.0% to 100%). 73 subjects were reactive on **cobas**® Malaria but negative on microscopy; ALT NAT results confirmed 72 subjects as status-positive (current infection) and 1 subject as status-negative (past infection based on the presence of antibody). **cobas**® Malaria detected *Plasmodium* nucleic acid (confirmed reactive) in 72 samples where no evidence of infection was detected with microscopy or antigen tests, methods commonly used to detect malaria infection in endemic areas.

Additional information

Key test features

Sample type	Whole blood in Roche Whole Blood Collection Tube
Amount of sample required	850 µL
Amount of sample processed	500 µL

Symbols

The following symbols are used in labeling for Roche PCR diagnostic products.

Table 43 Symbols used in labeling for Roche PCR diagnostics products

Age/DOB Age or Date of Birth	Device not for near-patient testing	QS IU/PCR QS IU per PCR reaction, use the QS International Units (IU) per PCR reaction in calculation of the results.
SW Ancillary Software	Device not for self-testing	
Assigned Range [copies/mL] Assigned Range (copies/mL)	Distributor *(Note: The applicable country/region may be designated beneath the symbol)*	SN Serial number
Assigned Range [IU/mL] Assigned Range (IU/mL)	Do not re-use	Site Site
EC REP Authorized representative in the European Community	Female	Procedure Standard Standard Procedure
BARCODE Barcode Data Sheet	For IVD performance evaluation only	STERILE EO Sterilized using ethylene oxide
LOT Batch code	GTIN Global Trade Item Number	Store in dark
Biological risks	Importer	Temperature limit
REF Catalogue number	IVD In vitro diagnostic medical device	TDF Test Definition File
CE CE marking of conformity; this device is in conformity with the applicable requirements for CE marking of an in vitro diagnostic medical device	LLR Lower Limit of Assigned Range	This way up
	Male	Procedure UltraSensitive Ultrasensitive Procedure
Collect Date Collect date	Manufacturer	UDI Unique Device Identifier
Consult instructions for use	CONTROL − Negative control	ULR Upper Limit of Assigned Range
Σ Contains sufficient for <*n*> tests	NON STERILE Non-sterile	Urine Fill Line Urine Fill Line
CONTENT Content of kit	Patient Name	Rx Only US Only: Federal law restricts this device to sale by or on the order of a physician.
CONTROL Control	Patient number	Use-by date
Date of manufacture	Peel here	
Device for near-patient testing	CONTROL + Positive control	
Device for self-testing	QS copies / PCR QS copies per PCR reaction, use the QS copies per PCR reaction in calculation of the results.	

Technical support

For technical support (assistance) please reach out to your local affiliate:
https://www.roche.com/about/business/roche_worldwide.htm

Manufacturer and importer

Table 44 Manufacturer and importer

Roche Molecular Systems, Inc.
US Highway 202 South
Branchburg, NJ 08876 USA
www.roche.com

Made in USA

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany

Trademarks and patents

See https://diagnostics.roche.com/us/en/about-us/patents

Copyright

EC REP

Roche Diagnostics GmbH
Sandhofer Str. 116
68305 Mannheim
Germany

CE
2797

IVD

References

1. Milner DA, Jr. Malaria pathogenesis. *Cold Spring Harb Perspect Med*. 2018;8:a025569.
2. World Health Organization. Malaria [factsheet]. Updated 29 March 2023; Accessed 26 April 2023. https://www.who.int/news-room/fact-sheets/detail/malaria.
3. World Health Organization. *A Framework for Malaria Elimination*. WHO Press: Geneva; 2017. Accessed: 25 April 2023. https://apps.who.int/iris/bitstream/handle/10665/254761/9789241511988-eng.pdf?sequence=1.
4. World Health Organization. *Screening Donated Blood for Transfusion-Transmissible Infections: Recommendations*. WHO Press: Geneva; 2009. Accessed: 23 February 2023. https://www.who.int/publications/i/item/9789241547888.
5. Verra F, Angheben A, Martello E, et al. A systematic review of transfusion-transmitted malaria in non-endemic areas. *Malar J*. 2018;17:36.
6. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. *N Engl J Med*. 2001;344:1973-8.
7. O'Brien SF, Delage G, Seed CR, et al. The epidemiology of imported malaria and transfusion policy in 5 nonendemic countries. *Transfus Med Rev*. 2015;29:162-71.
8. Kitchen AD, Chiodini PL, Tossell J. Detection of malarial DNA in blood donors--evidence of persistent infection. *Vox Sang*. 2014;107:123-31.
9. Mangano VD, Perandin F, Tiberti N, et al. Risk of transfusion-transmitted malaria: evaluation of commercial ELISA kits for the detection of anti-Plasmodium antibodies in candidate blood donors. *Malar J*. 2019;18:17.
10. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. *Gene*. 1990;93:125-8.
11. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. *Nature*. 1995;373:487-93.
12. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. *Cell*. 1995;80:869-78.
13. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. *Biotechnology (N Y)*. 1992;10:413-7.
14. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. *Genome Res*. 1996;6:986-94.
15. Centers for Disease Control and Prevention. *Biosafety in Microbiological and Biomedical Laboratories.* 5th ed. HHS Publication No. (CDC) 21-1112. US Department of Health and Human Services: Bethesda, MD (USA); 2009. Accessed: 25 April 2023. https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF.
16. Clinical and Laboratory Standards Institute. *Protection of Laboratory Workers from Occupationally Acquired Infections*. 4th ed. M29-A4. Clinical and Laboratory Standards Institute: Wayne, PA (USA); 2014.

Document revision

Document Revision Information	
Doc Rev. 1.0 05/2024	First Publishing

The summary of safety and performance report can be found using the following link: https://ec.europa.eu/tools/eudamed